Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pazopanib is an orally administered small molecule antineoplastic agent used primarily for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma in adults who have received prior chemotherapy. It acts as a second-generation, multitargeted tyrosine kinase inhibitor, selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta), and c-kit. By blocking these targets involved in angiogenesis pathways, pazopanib reduces tumor blood vessel formation necessary for tumor survival and growth. Pazopanib was originally developed by GlaxoSmithKline and is now marketed worldwide by Novartis under the brand name Votrient[1][4][5][6].
- Brand names
- Votrient
- Other names
- pazopanib hydrochloride
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on pazopanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib.